利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.017 秒)

    Detoxified TNF and method of preparing
    1.
    发明申请
    Detoxified TNF and method of preparing 审中-公开
    脱毒TNF及其制备方法

    公开(公告)号：US20060222624A1

    公开(公告)日：2006-10-05

    申请号：US11270276

    申请日：2005-11-09

    申请人： Tomas Bratt ,  Steen Klysner ,  Finn Nielsen ,  Soren Mouritsen ,  Bjorn Voldborg

    发明人： Tomas Bratt ,  Steen Klysner ,  Finn Nielsen ,  Soren Mouritsen ,  Bjorn Voldborg

    IPC分类号： A61K38/19 ,  C07K14/525 ,  C07H21/04 ,  C12P21/02 ,  C12N15/74 ,  C12N1/21

    CPC分类号： A61K39/0005 ,  A61K38/00 ,  A61K39/001 ,  A61K2039/523 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/525 ,  Y02A50/412

    摘要： The present invention provides for an immunogenic analogue of a human TNFα protein, wherein said analogue comprises an immunogenized monomeric TNFα polypeptide or TNFα di- or timer, and wherein the analogue further comprises a toxicity reducing or abolishing mutation selected from the group consisting of Y87S, D143N or A145R, the amino acid numbering setting out from the N-terminal valine in human TNFα. The invention also provides for a nucleic acid fragment encoding the analogue as well as to vectors and transformed cells useful in the preparation of the analogue. Also disclosed are methods of down-regulating TNFα in a subject in need thereof.

    摘要翻译： 本发明提供人TNFα蛋白的免疫原性类似物，其中所述类似物包含免疫原化的单体TNFα多肽或TNFα或二价或定时，其中所述类似物还包含毒性降低或消除突变，其选自Y87S， D143N或A145R，人TNFα中N-末端缬氨酸的氨基酸编号。 本发明还提供编码类似物的核酸片段以及用于制备类似物的载体和转化细胞。 还公开了在有需要的受试者中下调TNFα的方法。

    Method for down-regulating GDF-8 activity
    2.
    发明授权
    Method for down-regulating GDF-8 activity 失效
    降低GDF-8活性的方法

    公开(公告)号：US07056512B1

    公开(公告)日：2006-06-06

    申请号：US09620586

    申请日：2000-07-20

    申请人： Steen Klysner ,  Soren Mouritsen ,  Torben Halkier

    发明人： Steen Klysner ,  Soren Mouritsen ,  Torben Halkier

    IPC分类号： A61K39/00 ,  A61K39/38

    CPC分类号： C07K14/475 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K48/00 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55522 ,  C07K2319/00

    摘要： Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

    摘要翻译： 公开了通过免疫接种生长分化因子8（GDF-8，肌生成抑制素）来增加肌肉质量的新方法。 免疫优选通过施用能够诱导针对同源GDF-8的抗体产生的GDF-8的类似物来实现。 特别优选的是作为免疫原的同源GDF-8，其通过引入一个或多个外来的免疫显性和混杂的T细胞表位而被修饰，同时基本上保留了同源的GDF-8的三级结构。 还公开了针对GDF-8的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和装置。 这些方法和手段包括鉴定有用的免疫原性GDF-8类似物的方法，制备类似物和药物制剂的方法，以及核酸片段，载体，转化细胞，多肽和药物制剂。

    Novel methods for therapeutic vaccination
    3.
    发明申请
    Novel methods for therapeutic vaccination 有权
    治疗性接种的新​​方法

    公开(公告)号：US20060008465A1

    公开(公告)日：2006-01-12

    申请号：US11202516

    申请日：2005-08-11

    申请人： Lucilla Steinaa ,  Soren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Hanning ,  Dana Leach ,  Klaus Nielsen ,  Gunilla Karlsson ,  Peter Rasmussen

    发明人： Lucilla Steinaa ,  Soren Mouritsen ,  Anand Gautam ,  Iben Dalum ,  Jesper Hanning ,  Dana Leach ,  Klaus Nielsen ,  Gunilla Karlsson ,  Peter Rasmussen

    IPC分类号： C07H21/04 ,  A61K39/00 ,  C07K14/82 ,  C12N1/21 ,  C12N1/18

    CPC分类号： C07K16/3069 ,  A61K39/0011 ,  C07K14/50 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/71 ,  C07K2317/34 ,  C12N2799/021 ,  Y02A50/412

    摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

    摘要翻译： 公开了一种用于诱导针对细胞抗原的细胞介导的免疫的方法。 更具体地，本发明提供了一种诱导针对弱抗原，特别是自身蛋白的细胞毒性T淋巴细胞免疫的方法。 该方法需要抗原呈递细胞被诱导以呈现弱抗原的至少一个CTL表位，并且同时呈现至少一种外来T辅助淋巴细胞表位。 在优选的实施方案中，抗原是癌特异性抗原，例如 PSM，Her2或FGF8b。 该方法可以通过使用传统的多肽疫苗接种，也可以通过使用活减毒疫苗或核酸接种来进行。 本发明还提供了PSM，Her2和FGF8b的免疫原性类似物以及编码这些类似物的核酸分子。 还公开了载体和转化的细胞。 本发明还提供了用于鉴定弱或非免疫原性抗原的免疫原性类似物的方法。